About Us




Orphan Therapeutics, LLC is a privately held drug development company. It was founded in 2003 with the purpose to develop and seek regulatory approval for terlipressin for the treatment of Hepatorenal Syndrome (HRS) type 1 primarily in the US.

In March 2010, Orphan Therapeutics licensed the New Drug Application (NDA) and its development rights for terlipressin to Ikaria Inc., which was acquired by Mallinckrodt plc in April 2015.

Orphan Therapeutics continued to assist the Mallinckrodt team through the FDA approval process, which was successfully completed with the FDA approval of Terlivaz (terlipressin) Injection to improve kidney function in adults with hepatorenal syndrome in September 2022. 

For information about Terlivaz (terlipressin) Injection please visit mallinckrodt.com



Our people



PETER TEUBER, PH.D.



FOUNDER & PRESIDENT

Peter has more than three decades of experience in the pharmaceutical industry (Hoffmann-La Roche, The Medicines Company, Orphan Therapeutics) and a proven track record of developing successful specialty pharmaceuticals (Xeloda®, Angiomax®, Terlivaz®).



CHRIS PAPPAS, M.D.



Dr. Pappas is a physician and Fellow of the American Association for the Study of Liver Disease with clinical care experience over 35 years in transplant hepatology. As a former executive with Hoffman-La Roche and as a consultant for Orphan Therapeutics, he continues his activities in clinical trial design, analysis and drug development of pharmaceuticals for patients with liver disease.



CANDICE TEUBER, PHARM.D.



Candice has over 25 years of experience in the pharmaceutical industry and has been providing regulatory strategic leadership and implementation at Hoffmann-La Roche and as a senior consultant to pharmaceutical companies of all sizes and stages of development.



ORPHAN THERAPEUTICS, LLC



Longboat Key, Florida, USA



info@orphantherapeutics.com